HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat

Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sarcomas. HR23b has been shown to be a potential biomarker for sensitivity to HDACi the...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelika Ihle, Michaela, Merkelbach‐Bruse, Sabine, Hartmann, Wolfgang, Bauer, Sebastian, Ratner, Nancy, Sonobe, Hiroshi, Nishio, Jun, Larsson, Olle, Åman, Pierre, Pedeutour, Florence, Taguchi, Takahiro, Wardelmann, Eva, Buettner, Reinhard, Schildhaus, Hans‐Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907056/
https://www.ncbi.nlm.nih.gov/pubmed/27499916
http://dx.doi.org/10.1002/cjp2.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907056/
https://www.ncbi.nlm.nih.gov/pubmed/27499916
http://dx.doi.org/10.1002/cjp2.35

Ejemplares similares